Rosalind Franklin University of Medicine and Science announced today that BLR Bio, a company in its Helix 51 incubator, ...
Most patients with systemic sclerosis require treatment with multiple modes of action, according to a presenter at Congress ...
Please provide your email address to receive an email when new articles are posted on . Nearly 10% of patients with systemic sclerosis had systemic sclerosis sine scleroderma, a subtype without skin ...
CARLSBAD, California — In 2003, researchers asked 303 patients with systemic sclerosis (scleroderma) what bothered them most about their disease from an aesthetic standpoint: Orofacial features, such ...
Patients who underwent autologous stem cell transplantation (ASCT) for diffuse cutaneous systemic sclerosis (dcSSc), also known as scleroderma, did no better than others receiving conventional ...
Although less common than other subtypes of systemic sclerosis (SSc), systemic sclerosis sine scleroderma (ssSSc) makes up more than 8% of SSc cases and "should not be neglected," according to a new ...
Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial ...
Extracellular vesicles, responsible for cell-to-cell communication, might be a driver of fibrosis in systemic sclerosis, according to a recent paper in Arthritis and Rheumatology. Characterized by ...
Systemic sclerosis (SSc) is a rare autoimmune disease that can harden the skin, impair blood flow, and damage internal organs such as the lungs and kidneys. But no two patients experience the disease ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of ...
Q: My daughter, who is 14-years-old, was diagnosed with localized scleroderma about three years ago, and I am finding out that not much is known on this disease. Could you tell be about it? Does it ...